Seres Therapeutics assumed with an Outperform at Oppenheimer

Oppenheimer assumed coverage of Seres Therapeutics with an Outperform rating and $12 price target. There was no change to the firm’s estimates or price target, and Oppenheimer’s rating remains intact.